Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Cytokinetics (CYTK) Ownership - Who Owns Cytokinetics?
934 Followers
Cytokinetics (CYTK) Ownership Overview
17.01% Insiders
37.26% Mutual Funds
21.12% Other Institutional Investors
24.62% Public Companies and Individual Investors
The ownership structure of Cytokinetics (CYTK) stock is a mix of institutional, retail and individual investors. Approximately 58.37% of the company’s stock is owned by Institutional Investors, 17.01% is owned by Insiders and 24.62% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Apr 09, 2024 | Fady Ibraham Malik Evp Research & Development | Sold | $2422918 |
| Dec 01, 2023 | Robert Blum President & Ceo,director | Sold | $412375 |
| Nov 15, 2023 | Robert Blum President & Ceo,director | Sold | $432125 |
| Nov 09, 2023 | Fady Ibraham Malik Evp Research & Development | Sold | $88500 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $1252 | |
| Dec 31, 2023 | Bought | $264162 | |
| Dec 31, 2023 | Sold | $417450 | |
| Dec 31, 2023 | Bought | $1597831 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 465,387 | Insider | 0.45% | 30,408,387 | |
| 153,233 | Insider | 0.15% | 10,012,244 | |
| 138,417 | Insider | 0.13% | 9,044,167 | |
| 32,153 | Insider | 0.03% | 2,100,877 | |
| 30,782 | Insider | 0.03% | 2,011,296 | |
| 24,778 | Insider | 0.02% | 1,618,995 | |
| 21,261 | Insider | 0.02% | 1,389,194 | |
| 18,653 | Insider | 0.02% | 1,218,787 | |
| 18,653 | Insider | 0.02% | 1,218,787 | |
| 15,000 | Insider | 0.01% | 980,100 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,104,142 | Institution | 2.97% | 217,631,396 | |
| 3,044,143 | Institution | 2.91% | 199,604,457 | |
| 2,500,993 | Institution | 2.39% | 175,344,619 | |
| 2,252,985 | Institution | 2.15% | 147,728,226 | |
| 1,468,843 | Institution | 1.40% | 102,980,583 | |
| 1,415,960 | Institution | 1.35% | 99,272,956 | |
| 1,141,947 | Institution | 1.09% | 74,877,465 | |
| 798,826 | Institution | 0.76% | 51,763,925 | |
| 751,467 | Institution | 0.72% | 49,273,691 | |
| 744,356 | Institution | 0.71% | 48,807,423 |
FAQ
Who Owns Cytokinetics (CYTK)?
According to the latest TipRanks data, approximately 21.12% of the company's stock is held by institutional investors, 17.01% is held by insiders, and 24.62% is held by retail investors.
What percentage of Cytokinetics (CYTK) stock is held by institutional investors?
According to the latest TipRanks data, approximately 21.12% of Cytokinetics (CYTK) stock is held by institutional investors.
What percentage of Cytokinetics (CYTK) stock is held by retail investors?
According to the latest TipRanks data, approximately 24.62% of Cytokinetics (CYTK) stock is held by retail investors.
Who owns the most shares of Cytokinetics (CYTK)?
Robert Blum owns the most shares of Cytokinetics (CYTK).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.